WEBULL
WebtradeDownload

Novo Nordisk (NVO) Shares Dropped, So What Is Driving Attention Now?

Simply Wall St · 1d ago

Novo Nordisk (NYSE:NVO) has been drawing attention after recent returns turned negative across multiple time frames, including the past month and past 3 months. This has prompted fresh questions about what the current share price already reflects.

That recent slide in Novo Nordisk’s share price, with a 1 month share price return down 18.65% and a year to date share price decline of 27.14%, comes on top of a 1 year total shareholder return down 32.81% and a 3 year total shareholder return down 55.76%. This suggests momentum has been fading as investors reassess both growth potential and perceived risks around the current US$38.17 price point.

Scan beyond the recent slide in Novo Nordisk and compare it with a hand picked 30 high quality undervalued stocks that may already be pricing in stronger balance sheets and more resilient cash flows.

Novo Nordisk still runs a large, established pharma operation in diabetes, obesity and rare disease, yet the share price slide to US$38.17 challenges that strength. Is this now a solid business trading at a fair valuation, or not?

Most Popular Narrative: 62.9% Undervalued

Set against the last close at $38.17, the most followed valuation story pegs Novo Nordisk’s fair value near $102.97, which frames the recent share price slide in a very different light.

The GLP-1 market is growing at an unprecedented rate, with global sales projected to more than double from 2025 levels to reach $190 billion to $200 billion by 2035, with some forecasts projecting the market to exceed $250 billion by 2030-2034 due to the expansion into new therapeutic areas and rapid adoption of oral treatments.

What is behind 60 investors see Novo Nordisk as 63% undervalued.

Based on this widely followed narrative fair value of $102.97 against the current $38.17 share price, Novo Nordisk is framed as significantly UNDERVALUED.

Still, Novo Nordisk’s story could unravel if key GLP-1 forecasts prove too optimistic or if regulators delay or block expected approvals for new indications.

Find out about the key risks to this Novo Nordisk narrative.

Next Steps

Feeling that Novo Nordisk’s story is being pulled in two directions right now. Act quickly, review both sides of the thesis, and weigh the 3 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Novo Nordisk?

If Novo Nordisk has sharpened your focus on pricing and risk, do not stop here. Use structured stock ideas to widen your opportunity set intelligently.

Use the Simply Wall St screener to quickly surface other potential opportunities that fit different goals and risk levels.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.